NEW
Font size
WorksheetsBiomarker
Total questions: 10
Worksheet time: 10mins
What are the primary benefits of biomarker-based staging in Alzheimer’s Disease?
A. Improves early detection and guides clinical trial participant selection
B. Replaces imaging techniques in all settings
C. Eliminates the need for clinical staging
D. Provides direct measurement of cognitive impairment
How do amyloid PET and tau PET imaging differ in their application for AD staging?
A. Amyloid PET measures tau distribution, while tau PET detects Aβ plaques
B. Amyloid PET detects Aβ plaques early, while tau PET correlates with disease severity
C. Both exclusively measure neurodegeneration
D. Tau PET is used only in preclinical AD stages
Why might fluid biomarkers provide an advantage over imaging techniques in certain clinical settings?
A. They require PET imaging to confirm accuracy
B. Fluid biomarkers have no limitations with respect to reproducibility
C. Imaging always yields consistent results across centers
D. They are less invasive and more cost-effective than imaging
What roles do early-stage biomarkers (e.g., p-tau231 and p-tau217) play in AD diagnosis?
A. They exclusively measure neurodegeneration
B. They show changes only in late-stage AD
C. They help in identifying disease before clinical symptoms appear
D. They are only useful for patients with cognitive symptoms
How does the Centiloid scale contribute to the standardization of amyloid PET measurements?
A. It standardizes tau PET tracer measurements
B. It provides a common reference for amyloid PET results across different studies
C. It identifies cognitive decline stages directly
D. It eliminates the need for biomarker-based staging
What are some limitations of using biomarker-based staging systems in diverse populations?
A. Biomarkers detect cognitive resilience accurately in all settings
B. Biomarkers are universally applicable without standardization
C. They do not need to account for demographic differences
D. Variability in biomarker levels and representation across populations
In what ways could the inclusion of tau PET enhance the predictive value of AD staging systems?
A. By providing a closer correlation with cognitive symptoms than amyloid PET
B. By eliminating the need for amyloid PET in AD diagnosis
C. By measuring only Aβ plaque accumulation
D. By being limited to asymptomatic stages of AD
What implications does the identification of AD subtypes have for clinical trials and treatment approaches?
A. It reduces the need for patient monitoring
B. It leads to a single, standard treatment for all patients
C. It allows for tailored treatment strategies based on pathology distribution
D. It only affects individuals with mild AD symptoms
Why is it important to use both clinical and biological markers when staging Alzheimer’s Disease?
A. Clinical markers alone are sufficient
B. They complement each other to provide a fuller picture of disease progression
C. Biomarkers replace the need for clinical markers
D. Only clinical markers indicate the severity of cognitive symptoms
How might biomarker-based staging influence the timing of interventions in disease-modifying clinical trials?
A. By allowing treatments to be administered before extensive neurodegeneration
B. By confirming that treatment is needed only in late-stage AD
C. By eliminating the need for clinical assessments
D. By focusing solely on cognitive testing
